The Netherlands-based Ofichem Group signed a definitive agreement to acquire Avivia, another Netherlands-based company that specializes in formulation development. Ofichem officials say the acquisition marks a significant step in the company’s strategy to become a fully integrated provider of development solutions across drug substance and drug product, with a focus on complex formulations.
Avivia is a CDMO with expertise in formulation development, analytical method development, dissolution testing, and excipient characterization. The acquisition is expected to strengthen Ofichem’s ability to offer deeper support from early-phase development through to GMP production.
“By integrating Avivia into the Ofichem Group, we are strengthening our ability to support customers from drug substance through R&D and small to large scale GMP manufacturing and reinforcing our commitment to innovation and customer-centricity,” said Weite H. Oldenziel, PhD, CEO, and owner of the Ofichem Group. “This acquisition complements our capabilities in Ter Apel and Leiden and enables us to offer broader, more integrated services to our global customers.”
“This move further supports our ambition to evolve as a science-led CDMO and deliver innovation-driven solutions to our customers with enhanced capability in solving complex formulation challenges,” Weite added.
The acquisition aligns with Ofichem’s broader M&A agenda and ongoing investment strategy. The company is exploring additional opportunities to strengthen capabilities in both Europe and North America, with a focus on innovative technologies and early-phase development services.
The post Ofichem Acquires Avivia to Expand Formulation Development Capabilities appeared first on GEN – Genetic Engineering and Biotechnology News.
